TMEM181

Across TCGA pan-cancer cohorts, TMEM181 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM181 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM181 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM181 expression acts as an unfavorable survival marker.

HNSC, LSCC, and PDAC are the cancer types where TMEM181 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.597	0.845	<.001	68	view →
LSCC	OS	Median	II,III,IV	0.762	0.947	.002	35	view →
PDAC	OS	Median	All	0.390	0.740	<.001	26	view →
LUAD	OS	Quartile	II,III,IV	0.416	0.923	.012	14	view →
CCRCC	OS	Median	III,IV	0.417	0.985	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM181–HNSC (OS)

Open the HNSC breakdown →